Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

C. C. Hofmeister, B. Jansak, N. Denlinger, E. H. Kraut, D. M. Benson, S. S. Farag

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As2O3) with DVd (Doxil™, vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followed by four cycles of DVd plus ATO with the ATO at 0.25 mg/kg IV twice per week. The most common grade 3 toxicities were hyperglycemia, hyponatremia, and hypocalcemia. There were four partial and no complete responses. We could not demonstrate that the addition of ATO with this schedule improved the response rate of MM to DVd.

Original languageEnglish (US)
Pages (from-to)1295-1298
Number of pages4
JournalLeukemia Research
Volume32
Issue number8
DOIs
StatePublished - Aug 1 2008

Keywords

  • Arsenic
  • Doxorubicin
  • Multiple myeloma
  • Vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this